ClinicalTrials.gg
CompletedNCT06662123Updated Mar 19, 2025

Pharmacokinetic and Safety Study of Subcutaneous and Intravenous Anifrolumab Delivered in Healthy Adult Participants

A Phase 1 interventional study of Anifrolumab in Healthy Volunteers, sponsored by AstraZeneca. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a randomized, Phase I, open-label, single-dose study to evaluate the PK, safety, and tolerability of anifrolumab administered to male and female healthy Chinese participants aged 18 to 55 years. Approximately 24 participants, who fulfill the eligibility criteria, will be administered anifrolumab via SC route or IV route, and participants will be randomized to the two arms in a 1:1 ratio.

Read the detailed description

The purpose of this study is to evaluate the PK, safety, and tolerability of a single dose of anifrolumab subcutaneously or intravenously administered to healthy Chinese participants aged 18 to 55 years. The primary study endpoints are PK standard endpoints. The secondary study endpoints are standard endpoints for safety assessment, including adverse events, serious adverse events, and clinical safety laboratory measurements. The participants must abstain from taking prescription or non-prescription drugs (including vitamins and dietary or herbal supplements) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) before the start of study intervention until completion of the follow-up visit, unless, in the opinion of the investigator and sponsor, the medication will not interfere with the study.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to complete the follow-up visit as required by the protocol.
  • Participant must be 18 to 55 years of age (both inclusive), at the time of signature of the ICF.
  • A of ≥ 18.5 to ≤ 26.0 kg/m2 and body weight of at least 45 kg for females and 50 kg for males at screening.
  • Capable of giving signed as described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • History of with some exceptions
  • History of alcohol or drug abuse within the past 2 years.
  • Any significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Subcutaneous

    Drug: Anifrolumab

  • Experimental
    Intravenous

    Drug: Anifrolumab

Interventions

  • Participants will receive a single SC or IV dose of anifrolumab at day 1

    Also known as: Saphnelo

06

What researchers measure

Primary outcomes

  1. SC and IV Arm: Area under the serum concentration-time curve from the pre-dose concentration extrapolated to infinity (AUCinf)

    The concentration of anifrolumab in serum will be determined (AUCinf will be derived).

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

  2. SC and IV Arm: Maximum observed serum (peak) concentration (Cmax)

    The concentration of anifrolumab in serum will be determined (Cmax will be derived).

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

  3. SC and IV Arm: Time to reach peak or maximum observed concentration (tmax)

    The concentration of anifrolumab in serum will be determined (tmax will be derived).

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

  4. SC and IV Arm: Area under the serum concentration-time curve from pre-dose concentration to time of last quantifiable concentration (AUClast)

    The concentration of anifrolumab in serum will be determined (AUClast will be derived).

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

  5. SC and IV Arm: half-life associated with the terminal slope of a semi-logarithmic concentration-time curve (t½λz)

    The concentration of anifrolumab in serum will be determined (t½λz will be derived).

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

  6. Bioavailability (F)

    The concentration of anifrolumab in serum will be determined (F will be derived).

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

  7. SC Arm: Apparent total body clearance of drug after extravascular administration (CL/F)

    The concentration of anifrolumab in serum will be determined (CL/F will be derived).

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

  8. SC Arm:Volume of distribution during the terminal phase after extravascular administration (Vz/F)

    The concentration of anifrolumab in serum will be determined (Vz/F will be derived).

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

  9. IV Arm: volume of distribution during the terminal phase after intravenous administration (Vz)

    The concentration of anifrolumab in serum will be determined (Vz will be derived).

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

  10. IV Arm: Apparent total body clearance of drug after intravenous administration (CL)

    The concentration of anifrolumab in serum will be determined (CL will be derived).

    Time frame: At predefined intervals throughout the study period (From Day 1 to Day 57)

Secondary outcomes

  1. Adverse Event

    Assessments related to AEs cover * Occurrence/frequency * Relationship to study intervention as assessed by investigator * Intensity * Seriousness * Death * AEs leading to discontinuation of study intervention * AESI

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

  2. Vital Signs of blood pressure

    * Observed value * Absolute change from baseline values over time * Vital sign status including change in abnormality (eg, low, normal, high) from baseline to minimum/maximum postbaseline value * Treatment-emergent changes outside predefined criteria

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

  3. 12-lead ECG measurements include heart rate, RR interval, PR interval, QRS duration, and QT interval

    Assessments related to ECG cover: * Observed value * Absolute change from baseline values over time * ECG reading at baseline and each scheduled visit (normal, abnormal - clinically not significant, abnormal - clinically significant) including shifts in ECG interpretation compared to baseline * Treatment-emergent changes outside predefined criteria

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

  4. Safety haematology laboratory parameters: WBC, Neutrophils absolute count, RBC, Lymphocytes absolute count, Hb, Monocytes absolute count, HCT, Eosinophils absolute count, MCV, Basophils absolute count, MCH, Platelets, MCHC, Reticulocytes absolute count

    Assessments related to clinical laboratory safety * Observed value * Absolute change from baseline values over time * Laboratory status including change in abnormality (eg, low, normal, high) from baseline to minimum and maximum postbaseline value * Treatment-emergent changes in laboratory parameters outside predefined criteria Urinalysis categorisation as collected in the database including change in categorisation from baseline to the last post-baseline value.

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

  5. Physical examination of height

    Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the baseline assessment will be reported as an AE unless unequivocally related to the disease under study.

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

  6. Vital Signs of pulse rate

    * Observed value * Absolute change from baseline values over time * Vital sign status including change in abnormality (eg, low, normal, high) from baseline to minimum/maximum postbaseline value * Treatment-emergent changes outside predefined criteria

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

  7. Vital Signs of body temperature

    * Observed value * Absolute change from baseline values over time * Vital sign status including change in abnormality (eg, low, normal, high) from baseline to minimum/maximum postbaseline value * Treatment-emergent changes outside predefined criteria

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

  8. Vital Signs of respiratory rate

    * Observed value * Absolute change from baseline values over time * Vital sign status including change in abnormality (eg, low, normal, high) from baseline to minimum/maximum postbaseline value * Treatment-emergent changes outside predefined criteria

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

  9. Safety clinical chemistry laboratory parameters: Sodium, CRP, Potassium, ALP, Urea, ALT, Creatinine, AST, Albumin, GGT, Calcium, TBL, Phosphate, Conjugated bilirubin, Glucose, Creatine kinase

    Assessments related to clinical laboratory safety * Observed value * Absolute change from baseline values over time * Laboratory status including change in abnormality (eg, low, normal, high) from baseline to minimum and maximum postbaseline value * Treatment-emergent changes in laboratory parameters outside predefined criteria Urinalysis categorisation as collected in the database including change in categorisation from baseline to the last post-baseline value.

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

  10. Safety urinalysis laboratory parameters: Glucose Protein, Blood, Microscopy (if positive for protein or blood)

    Assessments related to clinical laboratory safety * Observed value * Absolute change from baseline values over time * Laboratory status including change in abnormality (eg, low, normal, high) from baseline to minimum and maximum postbaseline value * Treatment-emergent changes in laboratory parameters outside predefined criteria Urinalysis categorisation as collected in the database including change in categorisation from baseline to the last post-baseline value.

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

  11. Physical examination of weight

    Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the baseline assessment will be reported as an AE unless unequivocally related to the disease under study.

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

  12. Physical examination of general appearance, the lungs, cardiovascular system, and the abdomen

    Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the baseline assessment will be reported as an AE unless unequivocally related to the disease under study.

    Time frame: From the time of signature of the ICF, throughout the study and including the follow-up period (approximately 12 weeks)

07

Study locations

1 site
  • Research Site
    Wuhan, 430022, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Jan 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2024
First posted
Oct 28, 2024
StartActual
Oct 21, 2024
Primary completionActual
Jan 10, 2025
CompletionActual
Jan 10, 2025
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06662123
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 28, 2024
Start date
Oct 21, 2024
Primary completion
Jan 10, 2025
Completion
Jan 10, 2025
Last update
Mar 19, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion